GeneDx Holdings (WGS) — Scaling AI-Driven Genomic DiagnosticsCompany Overview
GeneDx NASDAQ:WGS is a genomics leader in pediatric & rare disease diagnostics, leveraging whole exome/genome sequencing and AI analytics—a direct play on the $20B+ precision medicine market.
Data & Platform Edge
GeneDx Infinity™: 1M+ exomes/genomes analyzed—one of the largest global repositories, enabling faster, more accurate diagnostic yield and clinical insights.
FDA Breakthrough Designations: ExomeDx™ and GenomeDx™ recognized—supports reimbursement, hospital integratio
Fdaapproval
Is the Fortress of Precision Oncology Crumbling?In late 2025, the global diagnostics industry is poised for a potential paradigm shift as rumors circulate regarding Abbott Laboratories' advanced negotiations to acquire Exact Sciences. A favorable macroeconomic pivot catalyzes this potential consolidation; the Federal Reserve’s decision to cut interest rates has thawed the "capital winter," enabling cash-rich conglomerates like Abbott to leverage debt for high-value acquisitions. While Exact Sciences has demonstrated financial fortitude with r
ELong
$APLT : Timeline scenarios after confusing Press Release.Best Case :
Filing Window : Nov–Dec 2025 (minutes quickly allow filing with existing dataset + agreed analyses; no new trial)
FDA acceptance (≈60 days post-filing): Jan–Feb 2026
Decision Window : Jul–Aug 2026 (priority) or Nov–Dec 2026 (standard)
Why this could happen : FDA agrees that totality of evidence (biomarkers/PROs + OLE) is file-able despite primary miss; orphan setting, unmet need.
Base case :
Filing Window :Apr–Jun 2026 (FDA asks for prespecified re-analyses, new stats plans, and
A
Can Single-Use Robotics Topple Surgical Giants?Microbot Medical Inc. (NASDAQ: MBOT) has experienced a dramatic stock surge from $0.85 to $4.67, driven by the convergence of multiple strategic milestones that signal a potential disruption in the surgical robotics market. The company's flagship LIBERTY® Endovascular Robotic System received FDA 510(k) clearance in September 2025, marking the first single-use, remotely operated robotic solution for peripheral endovascular procedures. This breakthrough represents more than regulatory approval; it
AI in Biotech: The Future of Cancer Therapy?Lantern Pharma Inc. is making waves in the biotech sector, leveraging its proprietary RADR® AI platform to accelerate the development of targeted cancer therapies. The company recently achieved significant milestones, including FDA clearance for a Phase 1b/2 trial of LP-184 in a difficult-to-treat non-small cell lung cancer (NSCLC) subset. This patient population, characterized by specific genetic mutations and poor response to existing treatments, represents a substantial unmet medical need and
Can Pain Be Managed Without Addiction?Vertex Pharmaceuticals has achieved a monumental breakthrough in pain management, securing FDA approval for Journavx, the first new class of painkiller in over 20 years. This non-opioid drug introduces a paradigm shift, targeting pain signals directly at the source without the addictive risks associated with traditional analgesics. The significance of this development cannot be overstated, as it promises a new era where acute pain can be treated effectively and safely, potentially altering the l
PHAT Phantom Pharma to moonshot from upgrade LONGPHAT is now targeting 25-34 according to analysts. I am not surprised. It has a pipeline and
is pending approval for a medication product to treat a stomach bacteria that causes chronic
infection and symptoms are often refractory to long and elaborate treatment protocols. The
product is already in Asia and doing well in YoY reports. PHAT has partnered with another
pharma company to make regulatory and marketing inroads in the European market. My
portfolio is already heavy with medtech a
TSHA a medtech penny stock pumps on news and earnings LONGTSHA is a gene technology medical company which reported on its clinical trials for Rett
Syndrome which is a neurobehavioral disorder separate from others like autism or
schizophrenia. This could be a breakthrough medication for those who suffer from Rett.
TSHA102 could be heralded as a miracle treatment ( not a cure). Price had trended up
in February and then down in March and is now situated at the mean anchored VWAP.
Relative volumes are 5-10X the running mean. I am taking a sizeab
SRZN a Penny biotech LONGSRZN has had good momentum. It has no revenues. Clinical trials but a lot of cash. SRZN has
advanced trials underway for a product to treat alcoholic hepatitis presumably settling it down
before it becomes irreversible cirrhosis (only for patients who are alcohol-free) and also useful
for liver metabolic disorders from a genetic basis.
SRZN has been trending up for a week with a bit of a pause in the middle of it. It picked up
60% of its price while breaking out through the anchored VW
$RAIN Squeeze Target we are pumping 35%+ in the premarket over our past resistant below the 5$, now is our support , we going to see a potential resistant and selling pressure below 7.80$, if we did we need to see buying pressure happing above the 6.18$, to confirm the breaking for that resistant the next time, and continue to go up to the next price target around the 11.50$.
if we went below the 6.18$, that's mean the short are heavily positioned at 7.80$, and we going to see strong buying pressure above the 5$, c
CRXT 900% Upside Potential According to this analyst Clarus Therapeutics Holdings, Inc. (CRXT) Announced Initiation of Phase 4 Clinical Trial of JATENZO, the first and only FDA-approved oral softgel for testosterone replacement therapy in adult male.
On 3/31/2022 Serge Belanger from Needham & Company LLC brokerage set a Buy Rating for CRXT and a Price Target of $8.00, which is 9 times higher than the current price.
I think it can easily double.
Looking forward to read your opinion about it.
CLong
AYTU All Time Low | Fast Track Designation form FDA todayAYTU Aytu BioPharma announced today that the FDA has granted Fast Track designation to AR101, a protein kinase inhibitor, for the treatment of patients with Vascular Ehlers-Danlos Syndrome.
After the bullish news, AYTU stock hit the all time low level.
52 Week Range 0.76 - 7.20
LADENBURG THALM has a price target of $14.50 for the stock.
I think a reversal is imminent.
My price target is $5.25.
Looking forward to read your opinion about it.
SESN Price TargetOn 8/17/2021 Canaccord Genuity brokerage Lower Price Target for SESN giving a Buy rating from $7.00 to $3.00.
Sesen Bio (SESN) flagship drug candidate Vicineum, failed to obtain FDA approval, but they will try a second time to get the regulatory go-ahead for the bladder cancer treatment.
buying long term calls could be a strategy for this one. volatility is likely after they announce the second FDA submission.
SLong
QNRX Market Outperform Price Target !!Yesterday, JMP Securities Initiated Coverage on Quoin Pharmaceuticals, Ltd. (QNRX) with a Market Outperform rating and a price target of 8usd.
Quoin Pharmaceuticals (NASDAQ: QNRX) is positioned to deliver the first FDA-approved treatment for Netherton Syndrome, a devastating disorder which affects 1 in every 200,000 people worldwide.
This month, QNRX Signed Multiple Exclusive Distribution Agreements for in various regions of the globe for its Lead Asset, QRX003, for Netherton Syndrome.
My pr
ARDX 500mil Revenue Forecasts for a Penny Stock | The 10X call??Ardelyx, Inc. ARDX yesterday had one of the the highest the out of the money call options, due to the fact they plan to launch IBSRELA, the company's FDA approved treatment for irritable bowel syndrome with constipation (IBS-C) in adults, in the second quarter of 2022, that has a potential peak in revenue greater than 500mil per year.
Since ARDX’s Market Cap is only 191.663Mil, it has still a big upside potential. A decent 9X revenue means a potential 4.5 Billion market cap.
That`s why in th
SENS Senseonics upcoming catalyst! SENS Senseonics is waiting for FDA`s approval for the 180-day version of its Eversense CGM system.
Eversense can generate as much as $200 million in sales by 2025.
HC Wainwright sees a 6usd price target for it.
And let`s not forget it`s a meme stock.
SLong
ACXP cheaper than the public offeringAcurx filed a provisional patent application with the U.S. Patent and Trademark Office for use of ibezapolstat to treat C. difficile Infection (CDI) while reducing recurrence of infection and improving the health of the gut microbiome.
In January 2019, FDA granted "Fast Track" designation to ibezapolstat for the treatment of patients with CDI.
The Company successfully completed Phase 1 and Phase 2a clinical trials of ibezapolstat and in the second half of 2021.
(prnewswire.com)
ARDX Ardelyx FDA bad news. Last support for bounceThe FDA is unlikely to approve Ardelyx`s drug for dialysis patients.
Ardelyx received a letter from the FDA stating that deficiencies in the information provided had been found that would preclude discussion of approvals Ardelyx has sought.
The most likely target is the 1.6usd support line from which it can bounce up.
Familiar T/A on ITRM Well, doesn't this look familiar? ITRM tested is previous level of support AND resistance in a wide channel today. IDK what the sell-off was but I'm guessing the re-entry had something to do with speculation on the FDA data set to come out next month.
"At the end of May, Iterum provided an update on its New Drug Application with the U.S. Food and Drug Administration. Currently, the NDA is still under review by the FDA, and the PDUFA goal date is July 25th, 2021. Since the application review f
I
$NNOX - 5-month Ascending Triangle Opportunity (Pre-Breakout)$NNOX had an explosive upside move on Friday.
An upside breakout of this ascending triangle gives me the following targets:
TG1: 76.50
TG2: 86
TG3: 96.50
Invalidation under: 52.19
Leave some feedback below if you have any!
And don't forget to like and follow if you'd like more 👍























